Daily low-dose aspirin has long been considered a “wonder drug” for its cardioprotective effects, particularly in patients with pre-existing cardiovascular and cerebrovascular disease; however, despite decades of research, the use of aspirin to prevent a first event is less certain. In 2014, the Food and Drug Administration (FDA) responded to a citizen petition requesting the labeled indications for low dose aspirin be updated to include primary prevention. The FDA concluded that the evidence “fail[ed] to establish that aspirin reduces the risk of primary myocardial infarction (MI) in patients with a coronary heart disease (CHD) risk of 10% or more for over 10 years.” The Asprin to Reduce Risk of Initial Vascular Events (ARRIVE) study is intended to address this gap in our knowledge.
Guest Authors: Amy St. Amand, PharmD, BCPS and Christine Borowy, PharmD, BCPS
Music by Good Talk
LDL Limbo: How Low is Too Low?
Top Ten Things Every Clinician Should Know About the 2018 Antithrombotic Therapy Atrial Fibrillation Guidelines
Maybe Old is Gold? Newer Insulins Might Not Be Better – Just More Expensive
Using Controllers PRN for Mild Persistent Asthma – An Oxymoron?
The ZOE Trials – The Herpes Zoster Recombinant Subunit Vaccine — It’s Time to Upgrade!
Are You REAL-ly Paying Attention? The Importance of Attention Controls
Is it Time to “Step Up” Rescue Treatment for Asthma to Prevent Exacerbations?
Stop the Shots: Edoxaban vs Dalteparin in Cancer-Associated VTE Treatment
Hypertension – Time for Patients to Control the Wheel
Cutting Down HIV Treatment to a 2-Drug Regimen
Strategies for Managing Hypertension: Is the Paradigm Shifting?
Don’t Kid Yourself: Broad- versus Narrow-Spectrum Antibiotics in Children
Using Sotagliflozin In Tandem with Insulin: Weighing the Benefits in Type 1 Diabetes
Treating Opioid Use Disorder - X:BOT Offers a Pragmatic Approach
Can We KEEP Perimenopausal Women Sexually Satisfied?
Know When to Hold 'Em - Know When to Fold 'Em. Deprescribing in BPH.
ARCH Study: Is Romosozumab better than Alendronate for the Fracture-Prone?
SPRINTing towards lower BP goals : A re-analysis of the ACCORD-BP trial
Therapy for Early-Stage COPD: What is the GOLDen Regimen?
Inflammatory Statements about Cardiovascular Risk Reduction: The CANTOS Trial
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive